Pelthos Therapeutics Injectable Extended-Release Formulation for Pain Treatment
Summary
USPTO published patent application US20260108499A1 for Pelthos Therapeutics Inc., filed October 22, 2025, covering injectable pharmaceutical formulations for extended release comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof. The named inventors are Eric D. LANG, Simon Paul CHANDLER, Deshou JIANG, and Richard MALAMUT (Application No. 19365336). The formulations are intended for treatment of pain or providing peri-operative anesthesia or post-operative analgesia.
“The present invention relates to pharmaceutical formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof, for extended release, to methods for preparation thereof, and to uses thereof for treatment of pain or providing peri-operative anesthesia or post-operative analgesia.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
USPTO published patent application US20260108499A1 assigned to Pelthos Therapeutics Inc., covering injectable pharmaceutical formulations for extended release. The formulations comprise 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof. CPC classifications span A61K 9/0019, A61K 9/06, A61K 9/08, A61K 9/5031, A61K 47/02, A61K 47/10, A61K 47/14, A61K 47/24, A61K 47/32, A61K 47/38, A61K 47/44, and A61P 25/04.
For pharmaceutical companies and investors monitoring the competitive landscape, this published application signals Pelthos Therapeutics' entry into the extended-release injectable pain treatment space. While the patent is still pending, competitors developing similar formulations for peri-operative anesthesia or post-operative analgesia should assess their own IP positions against the compound claims disclosed. Generic or biosimilar manufacturers should evaluate whether alternative delivery technologies could achieve similar therapeutic outcomes without infringement.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INJECTABLE FORMULATIONS
Application US20260108499A1 Kind: A1 Apr 23, 2026
Assignee
PELTHOS THERAPEUTICS INC.
Inventors
Eric D. LANG, Simon Paul CHANDLER, Deshou JIANG, Richard MALAMUT
Abstract
The present invention relates to pharmaceutical formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof, for extended release, to methods for preparation thereof, and to uses thereof for treatment of pain or providing peri-operative anesthesia or post-operative analgesia.
CPC Classifications
A61K 31/426 A61K 9/0019 A61K 9/06 A61K 9/08 A61K 9/5031 A61K 47/02 A61K 47/10 A61K 47/14 A61K 47/24 A61K 47/32 A61K 47/38 A61K 47/44 A61P 25/04
Filing Date
2025-10-22
Application No.
19365336
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.